Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/24/2025

Renal Dysfunction in Multiple Myeloma: Light Chain Cast Nephropathy

Diagnostic Considerations

  • The National Comprehensive Cancer Network recommends that the presence of 20% plasma cells on bone marrow biopsy definitively establishes a clonal plasma cell disorder, which produces nephrotoxic monoclonal immunoglobulin or light chains 1
  • Renal insufficiency in myeloma is predominantly due to light chain cast nephropathy, where free light chains are filtered by glomeruli and precipitate in distal tubules, causing tubular obstruction and interstitial inflammation, as stated by the National Comprehensive Cancer Network 1
  • The combination of back pain, elevated creatinine, and confirmed plasma cell proliferation creates the pathophysiologic environment for light chain-mediated kidney injury, according to the National Comprehensive Cancer Network 1, 2

Pathophysiology and Diagnosis

  • The mechanism of injury in light chain cast nephropathy involves monoclonal free light chains (kappa or lambda) being filtered through glomeruli and overwhelming tubular reabsorption capacity, precipitating in distal tubules with Tamm-Horsfall protein to form obstructing casts, as described by the National Comprehensive Cancer Network 1
  • Contributing factors beyond light chains, such as hypercalcemia, volume depletion, and hyperuricemia, frequently coexist and exacerbate renal injury, but the fundamental problem is light chain production, according to the National Comprehensive Cancer Network 1
  • The National Comprehensive Cancer Network recommends serum protein electrophoresis, serum immunofixation, 24-hour urine protein electrophoresis, and serum free light chain assay to quantify and characterize the monoclonal protein 1

Management Principles

  • The National Comprehensive Cancer Network states that immediate myeloma therapy is essential, and bortezomib-containing regimens should be initiated as soon as possible to decrease production of nephrotoxic clonal immunoglobulin 1
  • Bortezomib is preferred for renal impairment, and bortezomib/dexamethasone regimens can be administered to patients with severe renal impairment and those on dialysis without requiring renal dose adjustment, as recommended by the National Comprehensive Cancer Network 1

REFERENCES

1

nccn guidelines insights: multiple myeloma, version 1.2020. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

2

nccn clinical practice guidelines in oncology: multiple myeloma. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2009